MPLT vs TERN vs INVA vs MDGL

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 18. 5% for Innoviva, Inc. (INVA). Innoviva, Inc. (INVA) offers the better valuation at 6. 7x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate Terns Pharmaceuticals, Inc. (TERN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +290. 8%, compared to +59. 5% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: MDGL returned +37. 4% versus MPLT's +59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 15β versus Madrigal Pharmaceuticals, Inc. 's 0. 62β — meaning MDGL is approximately 313% more volatile than INVA relative to the S&P 500. On balance sheet safety, Terns Pharmaceuticals, Inc. (TERN) carries a lower debt/equity ratio of 0% versus 59% for Madrigal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 18. 5% for Innoviva, Inc. (INVA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -39. 6% for MapLight Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INVA: 82.

1% to $40. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 15), +106. 1% 10Y return). Both have compounded well over 10 years (INVA: +106. 1%, MPLT: +59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MPLT is a small-cap quality compounder stock; TERN is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; MDGL is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.